New drug trial aims to tame sickle cell pain crises
NCT ID NCT07224360
Summary
This study is testing the safety of an experimental drug called anumigilimab in adults with sickle cell disease. Over 64 weeks, researchers will monitor side effects while participants receive injections of the drug or a placebo. The goal is to see if the treatment is safe and if it might reduce the painful episodes called vaso-occlusive crises that people with sickle cell disease experience.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jacobi Medical Center
RECRUITINGThe Bronx, New York, 10461, United States
-
Southern Specialty Research
RECRUITINGFlowood, Mississippi, 39232, United States
-
The Foundation for Sickle Cell Disease
RECRUITINGHollywood, Florida, 33023-6703, United States
Conditions
Explore the condition pages connected to this study.